Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study
Algernon has received approval to conduct a Phase 1 clinical study of an intravenous formulation (“IVF”) of AP-188 (“N,N-dimethyl tryptamine” or “DMT”) for the treatment of stroke in the Netherlands. The trial will be conducted at the Centre for Human Drug Research (“CHDR”) in Leiden. The Company plans to begin screening shortly and dose the first subject of the study in Q4, 2022.
San Francisco Decriminalizes Psychedelics
The city of San Francisco has joined cities like Detroit and Seattle as the latest to decriminalize psychedelics.
Sponsored by Supervisors Dean Preston (D) and Hillary Ronen (D), lawmakers have unanimously approved the decriminalization of psychedelics like psilocybin and ayahuasca. The measure doesn’t officially change any laws, instead requesting that police deprioritize psychedelics as being among “the lowest priority” for law enforcement.
MindMed Announces Positive Results from Collaborators’ Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal
Rob Barrow, CEO and Director of MindMed, stated: “This paper further reinforces the positive preliminary evidence for LSD in patients who suffer from anxiety disorders. These results are encouraging and supportive of our proprietary MM-120 product candidate in its potential to one day offer a therapeutic benefit for patients suffering from GAD after just a single-dose administration.”
- Data from University Hospital Basel (UHB) study supports the clinical development of MindMed’s proprietary MM-120 product candidate for Generalized Anxiety Disorder (“GAD”)
- Patient dosing in Phase 2b trial ongoing for MM-120 in GAD–
- MindMed currently owns and retains all clinical data and manufacturing rights for MM-120 and intends to continue broadening its intellectual property portfolio
Microdose Brings Psychedelics to the Concordia Summit
Microdose Psychedelic Insights is proud to announce its official partnership with the Concordia Annual Summit, presenting the first-ever Mental Health & Psychedelics Panel. The 2022 Concordia Annual Summit will convene from September 19th to September 21st in New York City. Concordia and Microdose are planning an essential conversation and reception alongside the UN General Assembly.
“I’m honored to have been able to bring Concordia and Microdose together, with the aspiration to advance a critical conversation on the regulatory reform necessary to unlock psychedelic health solutions globally,” said Isaac Gilmore, COO of Ginger Commerce and Former Navy SEAL.
Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual Ketamine Treatments At-Home
Braxia announced it has successfully launched KetaMD in Florida. KetaMD onboarded new patients and completed initial ketamine treatments. KetaMD, a wholly owned subsidiary of Braxia Scientific, is an innovative end-to-end telemedicine platform, that provides access to safe, affordable, reliable and potentially life-changing at-home ketamine treatments for people suffering from mental health disorders such as depression, bipolar disorder, anxiety and post-traumatic stress disorder (PTSD).
Optimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian History
Optimi announced that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history. The Company is licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, as well as functional mushrooms that focus on the health and wellness markets.
“Our mushrooms are some of the most tested products on the planet as we cross the lines between Pharmaceutical, Agriculture, Botanical, and Food testing quality assays,” said Optimi Chief Science Officer, Justin Kirkland. “This yield gives us the capacity and scale we need to advance our analytical schedule while also developing our product pipeline,” he added.